Levodopa: A Review of its Pharmacological Properties and Therapeutic Uses with Particular Reference to Parkinsonism

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003495-197102040-00002PMID 4340597
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia

  2014cited by this paper
• Oral L-dopa treatment of parkinsonism.

  2009cited by this paper
• Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems

  2005cited by this paper
• Treatment of Parkinson's disease with l-DOPA and decarboxylase inhibitor

  2004cited by this paper
• La barrière capillaire pour la dopa dans le cerveau et les différents organes

  2004cited by this paper
• [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

  1998cited by this paper
• Progressive supranuclear palsy.

  1972cited by this paper
• Parkinsonism and depression.

  1972cited by this paper
• How does L-dopa work in parkinsonism?

  1971cited by this paper
• The choreoathetoid movement disorder induced by levodopa

  1971cited by this paper
• The biochemistry of catecholamines in relation to Parkinson's disease.

  1971cited by this paper
• Black vomit after levodopa.

  1971cited by this paper
• The metabolism of L‐3–0‐methyldopa, aprecursor of dopa in man

  1971cited by this paper
• Long-lasting dyskinesia induced by levodopa.

  1971cited by this paper
• Reversal by levodopa of cholinergic hypersensitivity in Parkinson's disease.

  1971cited by this paper
• Alopecia and levodopa.

  1971cited by this paper
• Darkening of urine from patients treated with L-dopa.

  1971cited by this paper
• Observations on the efficacy of L-dopa in progressive supranuclear palsy.

  1971cited by this paper
• Levodopa's awakening effect on patients with Parkinsonism

  1971cited by this paper
• Effect of L-dopa on brain monoamines and their metabolites in Parkinson's disease.

  1971cited by this paper
• The blood-brain barrier for l-Dopa in the hypothalamus

  1971cited by this paper
• Levodopa in Parkinsonism: the Effects of Withdrawal of Anticholinergic Drugs

  1971cited by this paper
• Treatment of Parkinson's disease with amantadine and levodopa. A one-year study.

  1971cited by this paper
• Treatment of Parkinson's disease with L-dopa: a current appraisal.

  1971cited by this paper
• Sexual behavior during L-dopa treatment for Parkinsonism.

  1971cited by this paper
• Plasma DOPA response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor

  1971cited by this paper
• Levodopa in acne vulgaris.

  1971cited by this paper
• The clinical pharmacology of levodopa.

  1971cited by this paper
• L-Dopa and amantadine hydrochloride in extra-pyramidal disorders

  1971cited by this paper
• Postmenopausal bleeding: another side-effect of levodopa.

  1971cited by this paper
• Predicting the response to levodopa.

  1971cited by this paper
• L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

  1971cited by this paper
• Serum-monoamine-oxidase levels during levodopa therapy.

  1971cited by this paper
• Symposium on levodopa in Parkinson's disease. Clinical and pharmacological aspects. Clinical laboratory abnormalities.

  1971cited by this paper
• Incidence of Side Effects from Levodopa during the Introduction of Treatment

  1971cited by this paper
• Levodopa and anesthesia.

  1971cited by this paper
• Dopa and 3-O-methyldopa in cerebrospinal fluid of Parkinsonism patients during treatment with oral L-dopa.

  1971cited by this paper
• Cardiovascular effects of levodopa

  1971cited by this paper
• Controlled trial of amantadine hydrochloride in Parkinson's disease.

  1971cited by this paper
• Sleep in patients with Parkinson's disease and normal subiects prior to and following levodopa administration

  1971cited by this paper
• False neurotransmitters and hepatic failure.

  1971cited by this paper
• Levodopa in Parkinsonian patients with heart-disease.

  1971cited by this paper
• Levodopa: Alterations in behavior

  1971cited by this paper
• Clinical laboratory abnormalities

  1971cited by this paper
• Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays.

  1971cited by this paper
• Mental effects of high-dosage levodopa.

  1971cited by this paper
• 3-O-Methyldopa, a New Precursor of Dopamine

  1971cited by this paper
• Treatment of Parkinsonism with laevodopa

  1971cited by this paper
• L-Dopa in Parkinsonism and the Influence of Previous Thalamotomy

  1971cited by this paper
• The blood-brain barrier for L-dopa in the hypothalamus.

  1971cited by this paper
• L-dopa as a vitamin-B6 antagonist.

  1971cited by this paper
• Treatment of Parkinson's disease with levodopa and Ro 4‐4602

  1971cited by this paper
• Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L‐3, 4‐dihydroxyphenylalanine (L‐dopa)

  1971cited by this paper
• Emotional disturbance accompanying the treatment of parkinsonism with L‐dopa

  1971cited by this paper
• Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor.

  1971cited by this paper
• Parkinsonism and cardiac arrhythmias.

  1971cited by this paper
• The past, present and future of surgical procedures in Parkinson's disease.

  1971cited by this paper
• Status of the clinical evaluation of levodopa in the treatment of Parkinson's disease and syndrome

  1971cited by this paper
• Excretion of dopa metabolites.

  1971cited by this paper
• Treatment of Parkinson's disease with amantadine and levodopa. A one-year study.

  1971cited by this paper
• Augmentation of sodium and potassium excretion, glomerular filtration rate and renal plasma flow by levodopa.

  1971cited by this paper
• A preliminary report of Australian trials with L-dopa.

  1971cited by this paper
• Uptake of catecholamines into serotonergic nerve cells as demonstrated by fluorescence histochemistry

  1971cited by this paper
• Blocking the negative effects of pyridoxine on patients receiving levodopa.

  1971cited by this paper
• Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa

  1971cited by this paper
• Comparison of benefit from l-dopa in Parkinsonism with increase of amine metabolites in the CSF

  1971cited by this paper
• Long-term side-effects of levodopa.

  1971cited by this paper
• Absorption and Metabolism of L‐Dopa by the Human Stomach

  1971cited by this paper
• Effects ofl-dopa alone and in combination with dopa decarboxylase inhibitors on the arterial pressure and heart rate of dogs

  1971cited by this paper
• AMANTADINE HYDROCHLORIDE IN THE TREATMENT OF PARKINSONISM A CONTROLLED TRIAL

  1970cited by this paper
• The management of Parkinsonism.

  1970cited by this paper
• 5-hydroxytryptophan in parkinsonism.

  1970cited by this paper
• Reversible effect of L-dopa on tremor and catatonia induced by alpha-methyl-p-tyrosine.

  1970cited by this paper
• L-dopa in progressive supranuclear palsy.

  1970cited by this paper
• Torsion dystonia and spasmodic torticollis—results of treatment with L‐dopa

  1970cited by this paper
• A controlled study of L-DOPA in Parkinson's disease.

  1970cited by this paper
• L-Dopa in the treatment of parkinsonism.

  1970cited by this paper
• L-dopa, parkinsonism, and depression.

  1970cited by this paper
• Evaluation of L-dopa therapy in Parkinson's disease.

  1970cited by this paper
• Levodopa in drug-induced extrapyramidal disorders.

  1970cited by this paper
• Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.

  1970cited by this paper
• The Eaton Collaborative Study of levodopa therapy in parkinsonism

  1970cited by this paper
• Dopa-induced excitement in the cat. Its relationship to brain norepinephrine concentrations.

  1970cited by this paper
• Corticosteroid and growth hormone secretion in patients treated with L-dopa

  1970cited by this paper
• Levodopa, pyridoxine, and the burning feet syndrome.

  1970cited by this paper
• Treatment of Parkinsonism with Laevo-Dopa

  1970cited by this paper
• L-dopa treatment failure: explanation and correction.

  1970cited by this paper
• The fate of C14-dihydroxyphenylalanine (C14-dopa) in the whole mouse.

  1970cited by this paper
• Psychiatric symptoms in Parkinsonism.

  1970cited by this paper
• Rationale for the use of L‐dopa in the torsion dystonias

  1970cited by this paper
• Combined treatment of Parkinson's disease with amantadine and L-dopa.

  1970cited by this paper
• Electrocardiographic and behavioral effects ofl-DOPA in the guinea-pig

  1970cited by this paper
• Parkinson's disease. Recent advances in treatment.

  1970cited by this paper
• Miosis during L-Dopa Therapy

  1970cited by this paper
• Neurosurgical treatment of dystonia

  1970cited by this paper
• Parkinsonism and cardiac arrhythmias.

  1970cited by this paper
• Side-effects of L-dopa in postencephalic parkinsonism.

  1970cited by this paper
• Parkinsonism and cardiac arrhythmias.

  1970cited by this paper
• Aberrant mRNA in Parkinsonism: Support for Hypothesis from Studies with Chloramphenicol

  1970cited by this paper
• Metabolism of D- vs L-Dopa.

  1970cited by this paper

• Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency

  2025cites this paper
• Targeting the serotonergic system in the treatment of neurodegenerative diseases—emerging therapies and unmet challenges

  2025cites this paper
• LATENTIATED PRODRUG APPROACH OF DRUGS: AN OVERVIEW

  2021cites this paper
• Levodopa therapy for Parkinson disease: A look backward and forward

  2020cites this paper
• The expanding role of prodrugs in contemporary drug design and development

  2018cites this paper
• The action of monoterpenoids with promising antiparkinsonian activity on fertility of Drosophila melanogaster

  2017cites this paper
• Levodopa therapy for Parkinson disease

  2016cites this paper
• Complex formation of FeIII, CuII, and ZnII with l-3-(3,4-dihydroxyphenyl)alanine in aqueous solutions

  2014cites this paper
• Drugs and Depression

  2012cites this paper
• Interactions Between Levodopa and Other Drugs: Significance in the Treatment of Parkinson’s Disease

  2012cites this paper
• Antiparkinsonian Drugs: Pharmacological and Therapeutic Aspects

  2012cites this paper
• Levodopa and Decarboxylase Inhibitors: A Review of their Clinical Pharmacology and Use in the Treatment of Parkinsonism

  2012cites this paper
• Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease.

  2009cites this paper
• The short-term effect of nicotine chewing gum in patients with parkinson's disease

  2005cites this paper
• Psychopharmacological investigations of a lead-induced long-term cognitive deficit in monkeys

  2004cites this paper
• Importance of treatment of depression in assuring the most efficacious management of Parkinson's disease.

  2000cites this paper
• A randomized crossover trial of levodopa in congestive heart failure.

  1996cites this paper
• Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.

  1992cites this paper
• Selegiline

  1992cites this paper
• Therapeutic Applications of Drugs Acting on Peripheral Dopamine Receptors

  1990cites this paper
• Central and peripheral adrenergic receptor agonists in heart failure.

  1989cites this paper
• Effects of psychotropic drugs on human erection and ejaculation.

  1989cites this paper
• Systemic and coronary hemodynamic and neurohumoral effects of levodopa in chronic congestive heart failure.

  1988cites this paper
• Evaluation of long-term oral levodopa therapy in chronic congestive heart failure

  1987cites this paper
• Does unilateral dopamine deficit contribute to depression?

  1985cites this paper
• The inotropic effects of dopamine and its precursor levodopa on isolated human ventricular myocardium

  1985cites this paper
• Differential changes in dopaminergic receptor sensitivity induced by agonist drugs.

  1985cites this paper
• Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine.

  1984cites this paper
• Adverse Effects of Antiparkinsonian Drugs

  1981cites this paper
• Sexual behavior of the male schizophrenic: The impact of illness and medications

  1981cites this paper
• Drug-induced Psychiatric Disorders

  1981cites this paper
• [Effects of precursors and metabolites of catecholamines on motricity of isolated rat duodenum. Particular reference to dopamine].

  1979cites this paper
• Cardiovascular pharmacology: report of the Main Working Party.

  1979cites this paper
• Catecholamines: Role in Health and Disease

  1978cites this paper
• [Effect of DOPA and dopamine on the motility of isolated rat duodenum in vitro].

  1978cites this paper
• Fenoterol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Asthma

  1977cites this paper
• [Interaction of L-DOPA and pyridoxine (a review of the literature)].

  1977cites this paper
• [Bicyclic analogs of piperazine. XII. (1) - Synthesis of 3,8-diazabicyclo/3,2,1/octanes as potential antiparkinson agents].

  1977cites this paper
• Influence of route of administration on physiological availability of levodopa in dogs.

  1976cites this paper
• Clinical Pharmacokinetics of Levodopa in Parkinson’s Disease

  1976cites this paper
• [Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor)].

  1975cites this paper
• L-Dopa and the treatment of extrapyramidal disease.

  1975cites this paper
• [Side-effects of L-dopa therapy].

  1975cites this paper
• Effects of drugs on clinical laboratory tests.

  1975cites this paper
• Renal hemodynamic response to l-dopa during acute renal failure in man.

  1975cites this paper
• [Therapy of Parkinsonian syndrome using L-dopa. Current state and problems].

  1974cites this paper
• Variation of levodopa metabolism with gastrointestinal absorption site.

  1974cites this paper
• The acute toxicity of L-dopa.

  1974cites this paper
• Transamination is a Major Pathway of L-Dopa Metabolism following Peripheral Decarboxylase Inhibition

  1974cites this paper
• [Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].

  1974cites this paper
• Effect of chronic l‐DOPA administration on catecholamine metabolism in the rat

  1973cites this paper
• Comparison of the central effects of dopamine and epinine.

  1973cites this paper
• Behavioral effects of l-Dopa in schizophrenic patients

  1973cites this paper
• LEVODOPA IN PARKINSON'S DISEASE—AUSTRALIAN COLLABORATIVE TRIAL

  1973cites this paper